May 28, 2018Open Access

Intrathecal administration of autologous mesenchymal stromal cells for spinal cord injury: Safety and efficacy of the 100/3 guideline

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The present guideline for cell therapy is safe and shows efficacy in patients with SCI, mainly in recovery of sphincter dysfunction, neuropathic pain and sensitivity.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Vaquero et al. (Mon,) studied this question.

synapsesocial.com/papers/69dc5c274f901957bec103e9 https://doi.org/https://doi.org/10.1016/j.jcyt.2018.03.032

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury2017 · 133 citations
2An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de Hierro phase I/II clinical trial2016 · 122 citations
3International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use2010 · 2,586 citations
4Some relationships between subjective measures of pain1972 · 235 citations
5Neurogenic bowel dysfunction score2005 · 340 citations

Me gusta

Guardar

Ver artículo completo